Ticker brief

COGT COGENT BIOSCIENCES INC

Consumer, Non-cyclical · Biotechnology

last close
$31.21
1 day
-0.3%
14 days
+0.7%
mkt cap
$6.6B
signals 14d
23
authors 14d
5
crowd 14d
+1.0σ
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d42%IV/HV 0.95× (as of 2026-08-25)
Skew — 25Δ RR 30d+0.01725Δ call IV − put IV
Net dealer OI (NDOI)+0.35 normal5-session Δ +0.21 (as of 2026-05-28)
OI alarmquietlast alarm 2026-02-24 (z=2.2)
Sentiment — last 14 days
daily mean sentiment, 2026-10-04 → 2026-10-16 · now +0.52 (−1 bearish … +1 bullish)
Who spoke5
authorgradetrader scoresignalsmean sent
@Biotech2k1A+1.1118+0.64
@semodoughC-1.062+0.38
@MitchMartan98C-3.791+0.80
@Maximus_HollaC-2.131+0.40
@bioinvestor24A-0.871+0.50
Recent signals23of 23 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-16@Biotech2k1+0.70Added MIRM, COGT, SMMT and IMNM this morning. — The author explicitly reports adding four biotech positions.+5.7%
2026-10-16@semodough+0.35COGT was the most-mentioned M&A pick in a 90-participant Cantor survey.+5.7%
2026-10-16@semodough+0.40COGT is rated Outperform with a $55 target alongside KOL and survey analysis.+5.7%
2026-10-16@Biotech2k1+0.65The author presents a researched ranking of core biotech holdings, led by INSM.+5.7%
2026-10-15@Biotech2k1+0.70Identifies a basket of biotech names viewed as mispriced excellence.+5.8%
2026-10-14@Biotech2k1+0.55Discloses additions to existing MIRM and COGT positions.+10.9%
2026-10-13@Biotech2k1+0.70Names a ranked basket of top biotech ideas based on strong fundamentals.+11.1%
2026-10-13@bioinvestor24+0.50Speculates COGT may be acquired before peers because management may accept a low premium.+11.1%
2026-10-13@Biotech2k1+0.70Reports additional purchases in three biotech positions.+11.1%
2026-10-13@Biotech2k1+0.75Discloses 45% biotech weight, a 50% threshold and six core or potential holdings.+11.1%
2026-10-13@Biotech2k1+0.75Reports adding BBIO and COGT.+11.1%
2026-10-13@Biotech2k1+0.40Author discloses adding to an existing COGT position.+11.1%
2026-10-12@Biotech2k1+0.55Discloses biotech buying, 44.35% weighting and preferred value names.+4.8%
2026-10-12@Biotech2k1+0.70Discloses buying COGT below $30 and calls it worth buying.+4.8%
2026-10-09@Biotech2k1+0.65Bought half a LABD position at $7.50; bids the other half at $7 while long value biotech. — Explicit staged LABD entry hedges long positions in selected value-biotech names.+0.7%
2026-10-08@Biotech2k1+0.65Discloses 42.5% biotech allocation and identifies preferred holdings and valuation views.+3.8%
2026-10-08@Biotech2k1+0.65Discloses a second wave of purchases across four biotech stocks.+3.8%
2026-10-08@Biotech2k1+0.55Reports small purchases in four biotech names.+3.8%
2026-10-06@Biotech2k1+0.60Discloses buying numerous biotech positions during a sharp sector decline.+2.7%
2026-10-05@Maximus_Holla+0.40Calls COGT cheap and notes repeated bounces at the current area.+1.1%
2026-10-05@MitchMartan98+0.80COGT is worth buying here, with a stronger entry near $17 if the gap fills. — Explicitly recommends buying COGT now or lower near a $17 gap-fill level.+1.1%
2026-10-05@Biotech2k1+0.70Bought a small COGT position and may buy more if biotech falls further. — Discloses a small current entry with conditional additional buying.+1.1%
2026-10-04@Biotech2k1+0.60Names four biotech stocks as the author's top value opportunities.+0.6%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.